Busca un médico

Stephan D. Thome, M.D.

  1. Hematologist
  2. Oncologist

Publicaciones

  1. Baral B, Suleiman R, Fazer-Posorske CA, Ma DJ, McGarrah PW, Thome SD, Molina JR, Price KA, Halfdanarson TR, Fuentes HE. Advancing head and neck cancer management: Unveiling the diagnostic and therapeutic potentials of molecular profiling. Head Neck. 2024 Jul 20 Epub 2024 July 20
    View PubMed
  2. Cathcart-Rake EJ, Steinert K, Smith D, Lewis-Peters S, Giridhar K, Novotny P, Dauer D, O'Connor A, Thome S, Erickson MK, Friday BB, Loprinzi CL. Rose geranium in sesame oil nasal spray to improve nasal vestibulitis symptoms: a randomized controlled trial. Support Care Cancer. 2024 May 24; 32 (6):379
    View PubMed
  3. Smith RS, Foster NR, Jatoi A, Thome SD, Miller RC. Incidence of Brain Metastasis as First Event in Patients with Esophageal Carcinoma: a Report from Three Prospective Alliance Clinical Trials. J Gastrointest Cancer. 2023 Sep; 54 (3):846-854 Epub 2022 Oct 17
    View PubMed
  4. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. A five arm natural history study of nasal vestibulitis. Cancer Med. 2023 Apr; 12 (8):9650-9654 Epub 2023 Apr 05
    View PubMed
  5. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. Support Care Cancer. 2021 Nov; 29 (11):6253-6258 Epub 2021 Apr 13
    View PubMed
  6. Leung N, Thome SD, Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 2018 Mar; 103 (3):e135-e137 Epub 2018 Jan 19
    View PubMed
  7. Grass S, Preuss KD, Thome S, Weisenburger DD, Witt V, Lynch J, Zettl F, Trumper L, Fadle N, Regitz E, Lynch H, Pfreundschuh M. Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. Blood. 2011 Jul 21; 118(3):635-7. Epub 2011 May 17.
    View PubMed
  8. Lynch HT, Synder CL, Lynch JF, Thome S. Familial plasma cell disorders and associated cancers. Clin Lymphoma Myeloma Leuk.2011;11:(1):80-1.
  9. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46.
    View PubMed
  10. Coleman EA, Lynch H, Enderlin C, Stewart B, Thome SD, Kennedy R, Richardson-Nelson T, Barlogie B. Initial report of a family registry of multiple myeloma. Cancer Nurs. 2009 Nov-Dec; 32(6):456-64.
    View PubMed
  11. Lynch HT, Thome SD. Familial multiple myeloma. Blood. 2009; 114(4):749-50.
  12. Lynch HT, Ferrara KM, Weisenburger DD, Sanger WG, Lynch JF, Thome SD. Genetic counseling for DAPK1 mutation in a chronic lymphocytic leukemia family. Cancer Genet Cytogenet. 2008 Oct 15; 186(2):95-102.
    View PubMed
  13. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, Sanger W, Watson P, Nipper H, Witt V, Thome S. Familial myeloma. N Engl J Med. 2008 Jul 10; 359(2):152-7.
    View PubMed
  14. Thome S. Review: erythropoiesis-stimulating agents increase mortality and venous thromboembolism in cancer-associated anemia. ACP J Club. 2008; 149(2):95-102.
  15. Thome S. Review: erythropoiesis-stimulating agents increase mortality and venous thromboembolism in cancer-associated anemia. Evid Based Med. 2008; 149(2):8.
  16. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15; 22 (10):1797-806 Epub 2004 Apr 05
    View PubMed
  17. Thome SD, Loprinzi CL, Heldebrant MP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin Proc. 2002 Sep; 77(9):913-7.
    View PubMed
  18. Rao RD, Thome SD, O'Fallon J, Earle JD, Dinapoli RP, Buckner JC. Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53 (2):376-84
    View PubMed
  19. Hogan MC, Lee A, Solberg LA, Thome SD. Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol. 2002 May; 70(1):55-9.
    View PubMed
  20. Menke DM, Chadbum A, Cesarman E, Green E, Berenson J, Said J, Tiemann M, Parwaresch R, Thome SD. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol. 2002 Feb; 117 (2):268-75
    View PubMed
  21. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol. 2001 Feb 15; 19 (4):972-9
    View PubMed
  22. Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thome S, Horowitz MM. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med. 2000 Oct 3; 133(7):504-15.
    View PubMed
  23. Thome SD, Wahner-Roedler DL. 71-year-old woman with palpitations and dyspnea on exertion. Mayo Clin Proc. 1998 Nov; 73(11):1109-12.
    View PubMed
  24. Schrezenmeier H, Thome SD, Tewald F, Fleischer B, Raghavachar A. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol. 1993 Feb; 21(2):358-65.
    View PubMed
PST-20227064